The new indication makes the cervical implant compatible with Attrax Putty, NuVasive’s synthetic bone graft substitute, according to a news release. The putty was first approved for thoracolumbar interbody fusion in December 2021.
“This clearance represents a significant milestone towards that goal, expanding our advanced materials combination of Modulus and Attrax Putty to our cervical interbody within the C360 portfolio,” Ryan Donahoe, NuVasive’s chief technology officer, said in the release.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
